VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwMyeloma 2015 | Optimizing proteasome inhibitors for the treatment of multiple myeloma

Robert Orlowski • 11 Apr 2015
iwMyeloma 2015
Multiple Myeloma

At the Myeloma 2015 meeting, Prof Robert Orlowski (MD Anderson Cancer Center, Houston, TX) discusses multiple novel proteasome inhibitors in clinical development that have shown promising activity for the treatment of multiple myeloma. Rationally based combination therapies involving proteasome inhibitors may offer a new option to overcome drug resistance.

More from Robert Orlowski

8:03
How can novel targets be incorporated into MM treatment?
Faith Davies et al.

Related Videos

4:28
A.R.R.O.W. study: carfilzomib dosing in frail MM patients
Maria-Victoria Mateos
1:16
Managing CRS in myeloma
Nina Shah
2:26
Managing transplant patients during the COVID-19 pandemic
Christian Chabannon
3:43
DNA methyltransferase inhibitors: daratumumab enhancement for MM
Priya Choudhry
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals